# Safety and Tolerability of Dalfampridine in Subjects With Cerebral Palsy

> **NCT01468350** · PHASE1 · COMPLETED · sponsor: **Acorda Therapeutics** · enrollment: 35 (actual)

## Conditions studied

- Cerebral Palsy (CP)

## Interventions

- **DRUG:** dalfampridine-ER 10mg
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT01468350
- **Lead sponsor:** Acorda Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-12
- **Primary completion:** 2013-01
- **Final completion:** 2013-03
- **Target enrollment:** 35 (ACTUAL)
- **Last updated:** 2014-06-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01468350

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01468350, "Safety and Tolerability of Dalfampridine in Subjects With Cerebral Palsy". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01468350. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*